. Author manuscript; available in PMC: 2020 Nov 2.

Published in final edited form as: Cancer Prev Res (Phila). 2013 Nov;6(11):1242–1250. doi: 10.1158/1940-6207.CAPR-13-0203

Table 3.

HPV16 and HPV18 antibody stability between months 24, 36, and 48 by number of doses

		1-dose	2-doses_(0/1)	2-doses_(0/6)	3-doses
			(Stable between 24–48 month)
			n (%)
HPV16
	Stable	67 (85.90)	137 (97.86)	52 (100)	119 (99.17)
	Increase	11 (14.10)	3 (2.14)	0	1 (0.83)
HPV18
	Stable	74 (94.87)	133 (95.00)	52 (100)	120 (100)
	Increase	4 (5.13)	7 (5.00)	0	0
			(Stable between 36–48 month)
			n (%)
HPV16
	Stable	72 (92.31)	136 (97.14)	52 (100)	119 (99.17)
	Increase	6 (7.69)	4 (2.86)	0	1 (0.83)
HPV18
	Stable	75 (96.15)	137 (97.86)	51 (98.08)	117 (97.50)
	Increase	3 (3.85)	3 (2.14)	1 (1.92)	3 (2.50)

HPV16 Spearman’s rank correlation coefficient at 24- and 48-month visits was 0.88 (P < 0.0001).

HPV18 Spearman’s rank correlation coefficient at 24- and 48-month visits was 0.90 (P < 0.0001).